Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer.

Jing Y, Chavez V, Ban Y, Acquavella N, El-Ashry D, Pronin A, Chen X, Merchan JR.

Mol Cancer Res. 2017 Oct;15(10):1410-1420. doi: 10.1158/1541-7786.MCR-17-0016. Epub 2017 Jul 5.


Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics.

Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, Kerkar SP, Michalek RD, Upham T, Leonardi A, Acquavella N, Wang E, Marincola FM, Gattinoni L, Muranski P, Sundrud MS, Klebanoff CA, Rosenberg SA, Fearon DT, Restifo NP.

Cancer Res. 2015 Jan 15;75(2):296-305. doi: 10.1158/0008-5472.CAN-14-2277. Epub 2014 Nov 28.


Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest.

Acquavella N, Clever D, Yu Z, Roelke-Parker M, Palmer DC, Xi L, Pflicke H, Ji Y, Gros A, Hanada K, Goldlust IS, Mehta GU, Klebanoff CA, Crompton JG, Sukumar M, Morrow JJ, Franco Z, Gattinoni L, Liu H, Wang E, Marincola F, Stroncek DF, Lee CC, Raffeld M, Bosenberg MW, Roychoudhuri R, Restifo NP.

Cancer Immunol Res. 2015 Jan;3(1):37-47. doi: 10.1158/2326-6066.CIR-14-0122. Epub 2014 Oct 30.


Renal cell carcinoma: trying but failing to improve the only curative therapy.

Acquavella N, Fojo T.

J Immunother. 2013 Nov-Dec;36(9):459-61. doi: 10.1097/CJI.0000000000000002. No abstract available.


Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

Ascierto PA, Grimaldi AM, Acquavella N, Borgognoni L, CalabrĂ² L, Cascinelli N, Cesano A, Del Vecchio M, Eggermont AM, Faries M, Ferrone S, Fox BA, Gajewski TF, Galon J, Gnjatic S, Gogas H, Kashani-Sabet M, Kaufman HL, Larkin J, Lo RS, Mantovani A, Margolin K, Melief C, McArthur G, Palmieri G, Puzanov I, Ribas A, Seliger B, Sosman J, Suenaert P, Tarhini AA, Trinchieri G, Vidal-Vanaclocha F, Wang E, Ciliberto G, Mozzillo N, Marincola FM, Thurin M.

J Transl Med. 2013 Jun 3;11:137. doi: 10.1186/1479-5876-11-137.


Meeting report: The future of preclinical mouse models in melanoma treatment is now.

Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M.

Pigment Cell Melanoma Res. 2013 Jul;26(4):E8-E14. doi: 10.1111/pcmr.12099. Epub 2013 Apr 8. No abstract available.


Therapeutic cancer vaccines: are we there yet?

Klebanoff CA, Acquavella N, Yu Z, Restifo NP.

Immunol Rev. 2011 Jan;239(1):27-44. doi: 10.1111/j.1600-065X.2010.00979.x. Review.


Effect of simvastatin on endothelial cell apoptosis mediated by Fas and TNF-alpha.

Acquavella N, Quiroga MF, Wittig O, Cardier JE.

Cytokine. 2010 Jan;49(1):45-50. doi: 10.1016/j.cyto.2009.09.011. Epub 2009 Nov 24.


Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.

Acquavella N, Kluger H, Rhee J, Farber L, Tara H, Ariyan S, Narayan D, Kelly W, Sznol M.

J Immunother. 2008 Jul-Aug;31(6):569-76. doi: 10.1097/CJI.0b013e318177a4ba.


Supplemental Content

Loading ...
Support Center